Related Experiment Video
Updated: Aug 8, 2026
09:03
Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells
Published on: November 23, 2014
Microtubule-targeting agents in angiogenesis: where do we stand?
Eddy Pasquier1, Stéphane Honoré, Diane Braguer
1FRE-CNRS 2737, CISMET (Cytosquelette et Intégration des Signaux du Micro-Environnement Tumoral), Université de la Méditerranée, 27 boulevard Jean Moulin, 13005 Marseille, France.
Summary
Microtubule-targeting agents (MTAs) show significant anti-angiogenic properties, crucial for inhibiting tumor growth and metastasis. Research explores their mechanisms, low-dose applications, and combination strategies for enhanced cancer chemotherapy.
Area of Science:
- Oncology
- Pharmacology
- Cancer Biology
Background:
- Angiogenesis, the formation of new blood vessels, is essential for tumor progression and metastasis.
- Targeting angiogenesis is a key strategy in cancer chemotherapy.
- Microtubule-targeting agents (MTAs) are effective anticancer drugs with potent anti-angiogenic activity.
Purpose of the Study:
- To review recent studies on the molecular and cellular mechanisms of MTA anti-angiogenic activity.
- To summarize pre-clinical and clinical findings on low-dose metronomic and combination strategies using MTAs.
- To discuss the future potential and limitations of MTAs in cancer therapy.
Main Methods:
- Review of recent scientific literature on microtubule-targeting agents and angiogenesis.
- Analysis of molecular and cellular mechanisms underlying anti-angiogenic effects.
- Summarization of pre-clinical and clinical study results.
Main Results:
- MTAs exhibit significant anti-angiogenic effects through various molecular and cellular pathways.
- Low-dose metronomic administration and combination strategies enhance the anti-angiogenic efficacy of MTAs.
- MTAs represent a promising class of agents for anti-angiogenic cancer therapy.
Conclusions:
- MTAs possess substantial anti-angiogenic potential, contributing to their efficacy in cancer treatment.
- Optimized dosing and combination therapies can maximize the anti-angiogenic benefits of MTAs.
- Further research and clinical development are warranted to fully realize the potential of MTAs in cancer chemotherapy.
Related Concept Videos
01:10Mechanism of Angiogenesis
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:24Regulation of Angiogenesis and Blood Supply
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
01:15Drugs that Stabilize Microtubules
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
01:10Drugs that Destabilize Microtubules
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...